METHODS FOR TARGETED CANCER TREATMENT AND DETECTION

• US 20110104074A1
• Filed: 06/18/2009
• Published: 05/05/2011
• Est. Priority Date: 06/18/2008
• Status: Abandoned Application

• Current Assignee: University of Louisville
• Original Assignee: University of Louisville
• Inventors: Kakar, Sham S.
• Application Number:
  US12/999,404
• Publication Number:
  US 20110104074A1
• Time in Patent Office: Days
• US Class Current: 424/9.32
• CPC Class Codes: A61B 5/055 involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 47/6911 the form being a liposome
• CPC Class Codes: A61K 47/6923 the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
• CPC Class Codes: C07D 209/30 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
• CPC Class Codes: C07D 413/12 linked by a chain containing hetero atoms as chain links

Abstract

A method for treating a cancer is provided that comprises identifying a subject in need of treatment for a cancer and administering to the subject a composition that is comprised of a plurality of a ligand for a luteinizing hormone-releasing hormone receptor and a plurality of a chemotherapeutic agent, where each ligand and each chemotherapeutic agent are conjugated to a nanoparticle. Further provided are methods for detecting a cancer in a subject that comprise administering to a subject an imaging agent comprised of a plurality of a ligand for a luteinizing hormone-releasing hormone receptor conjugated to a nanoparticle.

Claims

1. A method for treating a cancer in a subject, comprising:

identifying the subject in need of treatment for the cancer; and

administering to the subject an effective amount of a composition comprising a plurality of a chemotherapeutic agent and a plurality of a ligand for a luteinizing hormone-releasing hormone receptor, wherein each ligand and each chemotherapeutic agent are conjugated to a nanoparticle.

2. The method of claim 1, wherein the ligand for a luteinizing hormone-releasing hormone receptor comprises a luteinizing hormone-releasing hormone or an analog thereof.

3. The method of claim 2, wherein the ligand for a luteinizing hormone-releasing hormone receptor comprises a [D-Trp⁶] luteinizing hormone-releasing hormone.

4. The method of claim 1, wherein the plurality of the ligand for a luteinizing hormone-releasing hormone receptor comprises about 150 to about 250 molecules of the ligand.

5. The method of claim 4, wherein the plurality of the ligand for a luteinizing hormone-releasing hormone receptor comprises about 200 molecules of the ligand.

6. The method of claim 1, wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, oxaliplatin, paclitaxel, topotecen, and doxorubicin.

7. The method of claim 6, wherein the chemotherapeutic agent comprises doxorubicin.

8. The method of claim 1, wherein the plurality of the chemotherapeutic agent comprises about 50 to about 100 molecules of the chemotherapeutic agent.

9. The method of claim 1, wherein the plurality of the chemotherapeutic agent comprises about 75 molecules of the chemotherapeutic agent.

10. The method of claim 1, wherein the nanoparticle is a gold nanoparticle or a liposome.

11. The method of claim 10, wherein the nanoparticle is a pure gold nanoparticle.

12. The method of claim 1, wherein a concentration of the chemotherapeutic agent administered to the subject is about 5 μ

g/kg to about 15 μ

g/kg.

13. The method of claim 12, wherein the concentration of the chemotherapeutic agent is about 9.6 μ

g/kg.

14. The method of claim 1, wherein the cancer expresses a luteinizing hormone-releasing hormone receptor.

15. The method of claim 14, wherein the cancer is selected from breast cancer, ovarian cancer, prostate cancer, liver cancer, endometrial cancer, pancreatic cancer, melanoma, testicular cancer, pituitary cancer, uterine cancer, Non-Hodgkin'"'"'s lymphoma, and renal cell carcinoma.

16. The method of claim 1, wherein the composition is PEGylated.

17. The method of claim 1, wherein the plurality of the ligand for a luteinizing hormone-releasing hormone receptor comprises about 200 molecules of a [D-Trp⁶] luteinizing hormone-releasing hormone and the plurality of the chemotherapeutic agent comprises about 75 molecules of doxorubicin, and wherein the nanoparticle is a pure gold nanoparticle.

18. A method for detecting a cancer in a subject, comprising:

administering to the subject an effective amount of an imaging agent comprising a plurality of a ligand for a luteinizing hormone-releasing hormone receptor conjugated to a nanoparticle, wherein the ligand targets the imaging agent to the cancer in the subject; and

imaging the agent targeted to the cancer to thereby detect the cancer in the subject.

19. The method of claim 18, wherein the ligand for a luteinizing hormone-releasing hormone receptor comprises a luteinizing hormone-releasing hormone or an analog thereof.

20. The method of claim 19, wherein the ligand for a luteinizing hormone-releasing hormone receptor comprises a [D-Trp⁶] luteinizing hormone-releasing hormone.

21. The method of claim 18, wherein the nanoparticle is a pure gold nanoparticle.

22. The method of claim 18, wherein the cancer expresses a luteinizing hormone-releasing hormone receptor.

23. The method of claim 22, wherein the cancer is selected from breast cancer, ovarian cancer, prostate cancer, liver cancer, endometrial cancer, pancreatic cancer, melanoma, testicular cancer, pituitary cancer, uterine cancer, Non-Hodgkin'"'"'s lymphoma, and renal cell carcinoma.

24. The method of claim 18, wherein the agent is imaged by magnetic resonance imaging.